COCRYSTAL PHARMA, INC. Deferred Income Tax Expense (Benefit)
COCRYSTAL PHARMA, INC. (COCP) reported Deferred Income Tax Expense (Benefit) of -$13.58 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2020-03-27
- COCRYSTAL PHARMA, INC. deferred income tax expense (benefit) for the quarter ending 2011-03-31 was $7.06K.
- COCRYSTAL PHARMA, INC. deferred income tax expense (benefit) for fiscal 2019 was -$13.58M.
- COCRYSTAL PHARMA, INC. deferred income tax expense (benefit) for fiscal 2018 was -$13.58M.
- COCRYSTAL PHARMA, INC. deferred income tax expense (benefit) for fiscal 2017 was -$6.88M.
- COCRYSTAL PHARMA, INC. deferred income tax expense (benefit) for fiscal 2016 was -$29.41M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|
| 2019-12-31 | -$13.58M 10-K · filed 2020-03-27 | |
| 2018-12-31 | -$13.58M 10-K · filed 2020-03-27 | |
| 2017-12-31 | -$6.88M 10-K · filed 2019-04-01 | |
| 2016-12-31 | -$29.41M 10-K · filed 2018-03-21 | |
| 2015-12-31 | -$15.27M 10-K · filed 2018-03-21 | |
| 2014-12-31 | -$54.00K 10-K · filed 2017-03-31 | |
| 2011-03-31 | $7.06K 10-Q/A · filed 2012-10-02 | |
| 2010-12-31 | -$103.00K 10-K · filed 2012-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |